BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/30/2022 5:08:22 AM | Browse: 622 | Download: 1357
 |
Received |
|
2021-07-07 01:15 |
|
Peer-Review Started |
|
2021-07-07 01:21 |
|
First Decision by Editorial Office Director |
|
2021-09-28 07:17 |
|
Return for Revision |
|
2021-09-28 07:17 |
|
Revised |
|
2021-10-15 13:52 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-03-22 06:26 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-03-26 22:05 |
|
Articles in Press |
|
2022-03-26 22:05 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-04-19 02:16 |
|
Publish the Manuscript Online |
|
2022-04-30 05:08 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
COVID-19 and liver diseases, what we know so far
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mohamed Elnaggar, Ahmed Abomhya, Ismail Elkhattib, Nabila Dawoud and Rajkumar Doshi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mohamed Elnaggar, MD, Staff Physician, Department of Internal Medicine, University of Nevada Reno school of Medicine, 1155 Mill Street, W-11
, Reno, NV 89052, United States. mohamed.elnaggar.md@gmail.com |
| Key Words |
COIVD-19; SARS-CoV-2; Liver diseases; Transaminases; Non alcoholic fatty liver; Hepatocellular carcinoma |
| Core Tip |
On March 12, 2020, the World Health Organization declared that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was a pandemic. SARS-CoV-2 is notorious for causing gastrointestinal and liver injuries. Liver injury mechanisms include SARS-CoV-2-induced hepatic steatosis, reactivation of pre-existing liver disease, mitochondrial dysfunction, cardiomyopathy with hepatic congestion, immune-mediated damage, hypoxic hepatitis, direct cytotoxicity, drug-induced liver injury, ischemic hepatitis, microthrombotic disease, and extrahepatic release of transaminases. The coronavirus disease 2019 (COVID-19) pandemic has various effects on pre-existing liver conditions that range from care disruptions, exacerbation of liver condition, and higher mortality rates. It is necessary to know the mechanisms of liver injury in COVID-19 disease, epidemiology, clinical presentations, diagnosis, and effects on pre-existing liver conditions. |
| Publish Date |
2022-04-30 05:08 |
| Citation |
Elnaggar M, Abomhya A, Elkhattib I, Dawoud N, Doshi R. COVID-19 and liver diseases, what we know so far. World J Clin Cases 2022; 10(13): 3969-3980 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i13/3969.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i13.3969 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
